SCHEMBL4052810

SCHEMBL4052810

Clc1cccc(-c2cnc3cccnn23)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.65
DYRK3 O43781 4/20 0.65
CCNT1 O60563 4/20 0.65
CDK9 P50750 4/20 0.65
DYRK2 Q92630 4/20 0.65
DYRK1B Q9Y463 4/20 0.65
CDK5 Q00535 3/20 0.65
CDK5R1 Q15078 3/20 0.65
CCNA2 P20248 2/20 0.65
CDK2 P24941 2/20 0.65
EGLN2 Q96KS0 1/20 0.64
MKNK1 Q9BUB5 1/20 0.60
FYN P06241 3/20 0.56
CYP17A1 P05093 1/20 0.51
BACE1 P56817 1/20 0.50
PIM1 P11309 6/20 0.49
KCNH2 Q12809 1/20 0.49
KLK7 P49862 1/20 0.48
ABL1 P00519 1/20 0.48
BCR P11274 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16331591 0.83 MKNK1 (0.71) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL16331301 0.82 MKNK1 (0.60) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL29941012 0.82 DYRK1A (0.62) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL22189861 0.80 MKNK1 (0.77) DYRK1ADYRK3DYRK2DYRK1BCDK5
SCHEMBL16332085 0.79 EGLN2 (0.66) DYRK1AEGLN2MKNK1PIM1KLK7
SCHEMBL102942 0.79 DYRK1A (1.00) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL16332731 0.79 MKNK1 (0.60) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL22189894 0.78 EGLN2 (0.65) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL29555808 0.78 DYRK1A (0.67) DYRK1ADYRK3CCNT1CDK9DYRK2
SCHEMBL22189748 0.78 MKNK1 (0.56) DYRK1ADYRK3CCNT1CDK9DYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2024-02-08 US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 US disclosed
EP-2044071-A1 OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-04-08 EP disclosed
WO-2007147646-A1 OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B DYRK1A 228/4885DYRK3 265/4885CCNT1 4406/4885
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors FYN, LCK, PTK2B DYRK1A 228/4885DYRK3 265/4885CCNT1 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.